JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  05/23 04:00:01 pm EDT
179.44 USD   +2.04%
09:17aBayer's Xarelto Shows Long-Term Effect in Heart Disease Patients
MT
08:57aJOHNSON & JOHNSON : New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
PU
04:09aWhat We're Reading This Week
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DA Davidson Lifts Johnson & Johnson's Price Target to $196 From $188, Citing 'Increased Growth Potential;' Buy/Add Rating Kept

01/27/2022 | 05:36am EDT


© MT Newswires 2022
All news about JOHNSON & JOHNSON
09:17aBayer's Xarelto Shows Long-Term Effect in Heart Disease Patients
MT
08:57aJOHNSON & JOHNSON : New Data From Two Large Studies Reinforce Effectiveness of Dual Pathwa..
PU
04:09aWhat We're Reading This Week
AQ
05/23JOHNSON & JOHNSON : Ex-dividend day for
FA
05/20DOJ Objects to Cost of J&J Talc Unit Hiring Katyal For Appeal
DJ
05/20Top Midday Gainers
MT
05/20Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & J..
MT
05/19The Janssen Pharmaceutical Companies - New Data Show TREMFYA (guselkumab) Binds to Both..
AQ
05/19New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empa..
AQ
05/18Thinking about trading options or stock in Costco, Dollar Tree, Micron, Upstart, or Joh..
PR
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 500 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,2x
Yield 2022 2,48%
Capitalization 472 B 472 B -
EV / Sales 2022 4,80x
EV / Sales 2023 4,57x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 179,44 $
Average target price 186,82 $
Spread / Average Target 4,11%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099